AI & Digital Health

AI-powered personalized wellness ecosystem integrating blood pressure, glucose trends, meditation, weight optimization, and behavioral coaching — without entering regulated clinical territory

August 10, 2025

By Dr. Ebot Eyong

At E&E Medicals, we are excited to introduce eeMeds™, an AI-powered preventative wellness platform designed to unify fragmented lifestyle apps into a single adaptive personalization engine focused on sleep, stress, weight trends, movement, and behavioral optimization.

Read The Article

Partner With Dr. Eyong

At E&E Medicals, we are excited to introduce eeMeds™, our AI-powered preventative wellness platform. This innovative solution aims to unify fragmented lifestyle apps into a single, adaptive personalization engine, which we call "The AI-powered Lifestyle Intelligence Platform, or Your Personal Wellness Data Brain."

eeMeds goes beyond static content by dynamically optimizing user behavior across key areas, including sleep, stress, weight trends, and movement. Our focus is solely on wellness, allowing for rapid development and scalability.

We are currently raising a seed round to fund the following initiatives:

MVP and AI prototype development
Core engineering and product hires
Early beta launch and validation
Initial user-acquisition testing
Strategic wearable and ecosystem integrations

Our target for this seed raise is [$2.5M – $4.0M], which will support 12–18 months of product development and market validation. Our goal is to demonstrate strong early engagement, refine our personalization engine, and position eeMeds for scalable growth in future financing.

I would appreciate the opportunity for a brief conversation this week to share our vision and roadmap.

Best,

Dr. Ebot Eyong
Founder, E & E Medicals

For more information, visit https://eemedicals.com/

Explore More Publications

Continue exploring Dr. Ebot Eyong’s professional insights on healthcare regulation, FDA submissions, AI-enabled medical devices, quality systems, and global compliance strategy.

AI & Digital Health

Challenges in Medical Device AI Validation

June 18, 2026

Dr. Ebot Eyong

The most difficult aspect is ensuring that an AI system remains reliable after deployment as patient populations, clinical practices, and data characteristics evolve over time. This has led regulators to shift from a one-time validation model toward a lifecycle-based approach involving continuous monitoring and revalidation.

Read Article

Global Regulatory Strategy

One Medical Device, Multiple Regulatory Frameworks

August 10, 2024

By Dr. Ebot Eyong

A medical device may be engineered to a single design specification and validated to the same performance standards globally, but its regulatory pathway varies significantly depending on the market in which it is placed.

Read Article

Real-World Evidence

Real-World Evidence (RWE) and Biocompatibility: Implications of ISO 10993-1:2025 for Medical Device Manufacturers

December 11, 2025

By Dr. Ebot Eyong

The revised ISO 10993-1 marks a significant shift in biocompatibility assessment by enabling risk-based justifications supported by real-world evidence. This article explores pre-market submissions, manufacturer implications, AI-enabled device challenges, and regulatory pitfalls.

Read Article

CMC & FDA Submissions

Why is Module 3 (CMC) in FDA's New Drug Application (NDA) submission always challenging?

May 23, 2025

By Dr. Ebot Eyong

Despite thorough engagement with agencies such as the FDA, companies continue to face CMC and analytical issues that lead to Complete Response Letters. These issues often arise late, exposing gaps between sponsor expectations and FDA standards, especially in assay reproducibility, validation, and tech transfer.

Read Article

View All Publications